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Shypothesis as to who would likely benefit from LVRS, but
there was no stratification or separate analysis of this
prospectively identified group of patients. We hope that this
report, using the valuable repository of data collected by the
NETT trial, will help clarify the role of LVRS for selected
patients with emphysema. This is particularly important
inasmuch as none of the endoscopic procedures proposed in
an attempt to achieve a ‘‘volume reduction’’ effect (valves,
installation of adhesives, airway bypass) has demonstrated
sufficient efficacy to warrant Food and Drug Administration
approval at this time. Coupled with the reduction in priority
status for patients with chronic obstructive pulmonary disease
seeking a lung transplant, this potentially increases the
importance of LVRS for the management of selected
patients with severe chronic obstructive pulmonary disease.CONCLUSIONS
The current analysis of data obtained by the NETT im-
proves our ability to understand and clarify the current role
of LVRS. This analysis confirms that the NETT hypothesis
was indeed correct and that patients with heterogeneously
distributed upper lobe predominant emphysema achieved
significant benefit in terms of survival and functional im-
provement. We also conclude that for patients with a homo-
geneous pattern of emphysematous destruction, bilateral
LVRS offers no survival advantage and produces much
less functional improvement than in the heterogeneous upper
lobe predominant group.
This analysis of theNETTresults confirms,with remarkable
concordance, the previous report by Ciccone and associates3
of a 250 consecutive case series of bilateral LVRS.We suspect
that the similarity of results will contribute to the ongoing
debate as to the relativemerits of case–controlled series versus
randomized clinical trials for surgical procedures.References
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Dr Rodney J. Landreneau (Pittsburgh, Pa). This is a very nice
rehashing of what we have known for many years about LVRS. I
can remember when Jim Luketich joined me at the University of
Pittsburgh back in 1995 from Memorial. He believed it was like
a laminar air flow coming into the intensive care unit because of
all the negative suction coming from the chest tubes in place for
our LVRS patients. That was back in 1995 or so, right, Jim? By
1998, however, we had come to recognize that we were operating
on a lot of people erroneously, and then the NETT trial began.
If you look at the work of Dr Cooper’s group, who is leading us
out ofWashingtonUniversity, LarryKaiser’swork at theUniversity
of Pennsylvania,MikeMack inDallas, ourwork at theUniversity of
Pittsburgh, Dan Miller at Louisville at that time, and Dr Weder in
Europe, we all had come to this conclusion by 1998 that this is the
group of people we should be operating on. Again, we were led
by Dr Cooper’s group, and I re-emphasize their article from 2002.
I think that what has occurred is really concerning, as I hope Dr
Cooper will re-reiterate. The trend of publications off the NETT
trial was unfortunate and has basically resulted in the death or
near death of LVRS for a number of patients who could have
benefited over the past 6 to 7 years. To me, it is the abomination
of health care at its finest through government intervention, and I
think that we need to guard against subsequent forays like this in
the future. Although we certainly need to avoid unnecessary sur-
gery and to economize our use of the health-care dollar, I think
that this is just a case in point on how to kill an advantageous inter-
vention for a select group of patients. I look forward to hearing Dr
Cooper’s comments.
Dr Cooper. Rod, thank you very much.
As I think you indicated, the point of this presentation is not to
criticize the NETT trial. It is to try to extract from it finally, and for
the first time ever, exactly what it set out to do. Who are the most
appropriate patients? There was a reason for that hypothesis,
Rod, and that was based on what you and I and others had done,
and the hypothesis was based correctly on the experience to date.
However, the hypothesis specifically said upper lobe predominant,
with a heterogeneous pattern. The NETT trial developed 2 separate
criteria for the patterns of emphysema. One defined homogeneous
and heterogeneous and the other defined predominance—2 totally
different criteria. But the hypothesis said that both have to be pres-
ent: predominance, that is, the upper lobe should be worse than the
rest of the zones, and also heterogeneous, as defined by the severity
grade developed by the NETT trial. Each of the 3 lung zones wasery c September 2010
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Sgraded in terms of severity on a scale of 0 to 5. For the upper lung
zone to be defined as heterogeneous, it had to be at least 2 severity
grades worse than the other zones on the same side. The problem
was that when they reported the data, they contaminated the data,
so that their second publication was only based on predominance,
and many of the upper lobe predominant patients had homogeneous
distribution by their definition, and they mixed homogeneous and
heterogeneous patients together when reporting the data. It was
only because there was a hypothesis and because they specifically
outlined how to define upper lobe predominance and heterogeneity
that we can present this information and not be accused of post hoc
examination of the data. That was probably the most serious charge
against the final NETT report, that they diced and sliced the data
retrospectively. Therefore, I appreciate the comment. Yes, there
may be other patients who require individual judgment, but the
NETT trial showed in a randomized fashion that if the right patients
are selected, the right result is achieved. And I think it is astonishing
that a multicenter trial, comprising 17 centers, was able to accom-
plish exactly, identically the same results that we obtained with our
original single-center report. That usually does not happen. Multi-
center trials usually do not achieve the same results. They did. They
did it beautifully. They achieved exactly the same results. The prob-
lem was that the manner in which it was presented was very, very
confusing and confused the surgeons, the referring physicians, and
the patients. I guess the message is that if the right patients are
chosed, the right results will be achieved.
Dr Robert J. Cerfolio (Birmingham, Ala). I have a quick ques-
tion for you, Joel. We all know what has happened. The pulmonol-
ogists have sort of pulled the plug on LVRS. I do 1 or 2 a year. The
question now is with the new Spiration valves (Spiration, Inc, Red-
mond, Wash) or the other endobronchial valves. Is that going to in-
crease the number of people coming from LVRS, and if it does,
who do you think should get the valve, endobronchial therapy,
and who should get LVRS, and why?
Dr Cooper. Well, isn’t it interesting that the pulmonologists
who pooh-poohed LVRS nonetheless got the message that if you
reduce overinflation in emphysema patients, you transform their
lives to the point that they got interested in interventional proce-
dures. But, as you may or may not know, one valve company’s trial
was not approved. They are out of business. The second valve com-
pany’s preliminary data showed no benefit, and I have little doubt
that their pivotal trial will show no benefit. The third company,
which developed the gluing technique, I believe is no longer oper-
ational. The only thing that is still standing, and here I have a con-
flict, is the airway bypass, which was really not designed for
patients with heterogeneous distribution but was designed for those
patients with homogeneous distribution. Ideally, the fact that there
does not appear to be a bronchoscopically effective alternative and
the fact that the NETT trial shows that if you focus on the right
patients, you get excellent results, will rekindle interest in LVRS.
I would also like to note that the NETT report retrospectively
broke up the upper lobe predominant patients into 2 subgroups
based on the preoperative exercise capacity defined as either high
or low exercise capacity. When you now look at the appropriate up-
per lobe predominant patients, namely, those who meet the criteria
of upper lobe predominant and heterogeneous, then the outcome
after LVRS is exactly the same whether or not the patient had
a high or low exercise capacity. The message is that the mostThe Journal of Thoracic and Caappropriate patients for LVRS are those who have an upper
lobe predominant, heterogeneous distribution pattern of emphy-
sema. I believe that it is necessary to promulgate the NETT data
in a transparent fashion and to eliminate what I like to call the toxic
data included in their analysis, namely, the inclusion of both het-
erogeneous and homogeneous distribution in what was called their
upper lobe predominant patients. This will highlight the true value
of the NETT study and lead to a resurgence of appropriate use of
LVRS.
Dr Cerfolio. That was a circuitous answer. I think the valves do
work. So my question is, in what patient who comes to you would
you put the endobronchial valve in and to whom would you recom-
mend LVRS and why?
Dr Cooper. You are right. First of all, the question is, will they
be allowed to sell any valves? One company is out. Maybe they
will. I have often said to a patient, ‘‘If I could only wish away
your upper lobes, I know you would be better. You would have
less hyperinflation. Your work at breathing would be better. I can’t
wish it away. I have to subject you to an operation. You’ve got
cardiac issues. You’ve got vascular issues. I don’t think it’s worth
the risk in your case.’’ That is the patient, in my opinion, who
might be considered for the valves if they are approved. That is
the group of patients for whom I would like to have an alternative
to LVRS.
Dr Walter Weder (Zurich, Switzerland). You write in your ab-
stract that a lot of data are missing in the medical group of the
NETT. Could you elucidate this?
Dr Cooper. I had 3 slides. Flip through those slides.
Dr Weder. Were these data relevant or irrelevant?
Dr Cooper. Dr Weder, I was very surprised to see how much
data were missing, so much so that we were unable to carry out
our analysis after the third year. It turns out that although the
NETT trial was 5 years, they stopped collecting data (and maybe
that was built into it) after 2 to 3 years. But, Walter, there were 2
primary end points. One is survival. Of course they had death re-
cords. That’s immaculate. They clearly have 100% data there.
The other was workload. This slide says pulmonary function tests
and functional data. Functional data was the maximum workload.
As you can see, functional data are missing on 30% of the patients
who are alive at least 1 year after randomization, and by 3 years
more than 35% of patients are missing functional data. When I
showed this to a statistician, he pointed out that not only does
the NETT trial validate our previously reported data, but in fact
our data validate the NETT trial data because we had less than
10% missing data at every time point to 5 years, and since we
had the same apparent results as the NETT trial, it means that
the missing data in the NETT trial were probably not critical. Spe-
cifically, it probably means that the missing data did not selectively
represent patients with a bad result; therefore, they did not neces-
sarily bias the outcome. Nonetheless, it was a surprise to find
out how much missing data there was in this highly funded,
well-organized trial.
Dr David M. Follette (Sacramento, Calif). Joel, I want to com-
pliment you, and I would like to have you make a comment on an-
other point. One of the great contributions I found from your work
is that it has greatly expanded my ability to operate on patients with
lung cancer. As you well know, there is a subgroup of patients with
cancer who are said to be inoperable because of poor pulmonaryrdiovascular Surgery c Volume 140, Number 3 571
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Sfunction. Because of your work, which was nicely summarized to-
day, I have used similar criteria to evaluate these cancer patients. In
those patients with heterogeneous disease with isolated lung can-
cers in the poorly perfused areas, I have performed resection of
the area. These patients have not only had great results with respect
to their cancer but have also had remarkable improvement in their
pulmonary function and exercise capacity. Dr Cooper, have you
looked at this subgroup of patients with a diagnosis of severe em-
physema and lung cancer?
Dr Cooper. We have. We actually had an initial report of our
first 20 patients—FEV1s less than 30%, all oxygen-dependent—
who underwent an anatomic lobectomy with or without additional
resections for volume reduction purposes. I think there was 1 death
and an excellent survival curve.
I believe we have obtained 3 benefits from volume reduction sur-
gery other than the benefit for the LVRS patients themselves: (1)572 The Journal of Thoracic and Cardiovascular Surgimproved anesthetic and pain management with high-risk patients
undergoing lung cancer, (2) the benefit of exercise rehabilitation
in patients with emphysema, and (3) the recognition that if the can-
cer is in the right place, a simple lobectomy or lobectomy plus some
other volume reduction not only gets rid of the cancer but also gives
significant improvement in lung function. In our series there was an
average of 38% improvement in the first second vital capacity in the
lobectomy patients whose preoperative FEV1 was less than 30%,
who were oxygen-dependent, and who were not candidates for
lobectomy for their cancer, based solely on their risk factors.
One of the old-time surgeons told me about a patient who had
demanded a lobectomy for his cancer. It was an upper lobe cancer,
and the patient had severe emphysema and was a very high risk.
The surgeon said, ‘‘I went ahead and did it, and I got rid of the can-
cer and he breathed much better.’’ If he had told us that years ago,
we would have started LVRS earlier.ery c September 2010
